Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

Cancer Science

Volumn 98, Issue 8, 2007, Pages 1275-1280

  Kimura, Hideharu ^a,b   Sakai, Kazuko ^a   Arao, Tokuzo ^a,c   Shimoyama, Tatsu ^a,d   Tamura, Tomohide ^a   Nishio, Kazuto ^a,c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMC 225; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL ASSAY; CELL STRAIN HEK293; CELL STRAIN K 562; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; CYTOTOXICITY; DOSE RESPONSE; EXTRACELLULAR SPACE; GENE DELETION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION;

EID: 34347229786     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00510.x     Document Type: Article

References (22)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
2. Selvaggi G, Novello S, Torri V et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15: 28-32.
3. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997; 3: 2703-7.
4. de Bono JS, Rowinsky EK. The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 2002; 8: S19-26.
5. Mendelson J. Blockade of receptors for growth factors: An anticancer therapy - the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000; 6: 747-53.
6. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
7. Grillo-Lopez AJ, White CA, Varns C et al. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26: 66-73.
8. Vogel C, Cobleigh MA, Tripathy D et al. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: A preliminary report. Eur J Cancer 2001; 37: S25-9.
9. Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581-90.
10. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 2004; 64: 9101-4.
11. Naruse I, Fukumoto H, Saijo N, Nishio K. Enhanced anti-tumor effect of trastuzumab in combination with cisplatin. Jpn J Cancer Res 2003; 93: 574-81.
12. Mukohara T, Engelman JA, Hanna NH et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97: 1185-94.
13. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
14. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
15. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers'and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13.306-11.
16. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.
17. Nagai Y, Miyazawa H, Tanaka T et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 7276-82.
18. Bianco R, Daniele G, Ciardiello F, Tortora G. Monoclonal antibodies targeting the epidermal growth factor receptor. Curr Drug Targets 2005; 6: 275-87.
19. Graziano RF, Fanger MW. Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. J Immunol 1987; 139: 3536-41.
20. Dall'Ozzo S, Tartas S, Paintaud G et al. Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64: 4664-9.
21. Carson WE, Parihar R, Lindemann MJ et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001; 31: 3016-25.
22. Shinkawa T, Nakamura K, Yamane N et al. The absence of fucose but not the presence of galactose or bisecting N -acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-73.